Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 116 of the 117 references it cites were found in a registry or an index; 9 of the 58 sources its claims cite were checked for support.

Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease

Open access
Silva, Aderbal R. T., Santos, Ana Cecília Feio, Farfel, Jose M., Grinberg, Lea T., Ferretti, Renata E. L., Campos, Antonio Hugo Jose Froes Marques, Cunha, Isabela Werneck, Begnami, Maria Dirlei, Rocha, Rafael M., Carraro, Dirce M., de Bragança Pereira, Carlos Alberto, Jacob-Filho, Wilson, Brentani, Helena · 2014 · PLoS ONE

Abstract

Alzheimer's disease (AD) is characterized by progressive cognitive decline associated with a featured neuropathology (neuritic plaques and neurofibrillary tangles). Several studies have implicated oxidative damage to DNA, DNA repair, and altered cell-cycle regulation in addition to cell death in AD post-mitotic neurons. However, there is a lack of studies that systematically assess those biological processes in patients with AD neuropathology but with no evidence of cognitive impairment. We evaluated markers of oxidative DNA damage (8-OHdG, H2AX), DNA repair (p53, BRCA1, PTEN), and cell-cycle (Cdk1, Cdk4, Cdk5, Cyclin B1, Cyclin D1, p27Kip1, phospho-Rb and E2F1) through immunohistochemistry and cell death through TUNEL in autopsy hippocampal tissue samples arrayed in a tissue microarray (TMA) composed of three groups: I) "clinical-pathological AD" (CP-AD)--subjects with neuropathological AD (Braak ≥ IV and CERAD = B or C) and clinical dementia (CDR ≥ 2, IQCODE>3.8); II) "pathological AD" (P-AD)--subjects with neuropathological AD (Braak ≥ IV and CERAD = B or C) and without cognitive impairment (CDR 0, IQCODE<3.2); and III) "normal aging" (N)--subjects without neuropathological AD (Braak ≤ II and CERAD 0 or A) and with normal cognitive function (CDR 0, IQCODE<3.2). Our results show that high levels of oxidative DNA damage are present in all groups. However, significant reductions in DNA repair and cell-cycle inhibition markers and increases in cell-cycle progression and cell death markers in subjects with CP-AD were detected when compared to both P-AD and N groups, whereas there were no significant differences in the studied markers between P-AD individuals and N subjects. This study indicates that, even in the setting of pathological AD, healthy cognition may be associated with a preserved repair to DNA damage, cell-cycle regulation, and cell death in post-mitotic neurons.

Overview

CoChat Summary

TL;DR

In autopsy hippocampal tissue, subjects with AD neuropathology and clinical dementia (CP-AD) showed reduced DNA-repair/cell-cycle-inhibition markers and increased cell-cycle-progression and cell-death markers compared with both pathological AD without cognitive impairment (P-AD) and normal aging (N). P-AD subjects were largely indistinguishable from N subjects, suggesting preserved DNA repair and cell-cycle control may accompany resilient cognition despite AD pathology.

Key findings

  • Oxidative DNA damage markers were elevated in CP-AD versus N: nuclear 8-OHdG median 25 vs 15 (Dunn p=0.0145) and nuclear H2AX median 20 vs 7 (p=0.0001); high damage was present in all groups.
  • Nuclear DNA-repair markers were lower in CP-AD than in P-AD and N: p53 median 7 vs 14 and 15 (CP-AD vs N p<0.0001; CP-AD vs P-AD p=0.0222), and PTEN median 25 vs 31 and 27 (CP-AD vs P-AD p=0.0003; CP-AD vs N p=0.0093).
  • Cell-cycle progression markers (Cdk4, cyclin D, phospho-Rb, E2F1, Cdk1, cyclin B) were higher in CP-AD than in P-AD and N, while inhibitors p27 and Cdk5 were lower in CP-AD; apoptosis was higher in CP-AD (median 20) than P-AD (3.5) and N (0).
  • Hierarchical clustering separated all CP-AD samples from a combined P-AD + N cluster with 100% bootstrap support; P-AD and N showed no significant differences for the studied markers.

Methods

  • Post-mortem hippocampal CA1 tissue from the Brain Bank of the Brazilian Aging Brain Study Group was arrayed in a tissue microarray; groups were CP-AD (neuropathological AD plus dementia), P-AD (neuropathological AD without cognitive impairment), and N (normal aging), with Table 1 listing 19 CP-AD, 12 P-AD, and 31 N subjects (TMA construction text says 18 CP-AD).
  • Immunohistochemistry assessed oxidative DNA damage (8-OHdG, H2AX), DNA repair (p53, BRCA1, PTEN, phospho-AKT), and cell-cycle markers (Cdk1, Cdk4, Cdk5, cyclin B1, cyclin D1, p27Kip1, phospho-Rb, E2F1); TUNEL assessed cell death.
  • Nuclear and cytoplasmic positivity/intensity were scored semiquantitatively; group comparisons used Kruskal-Wallis with Dunn’s tests, and hierarchical clustering used Pearson correlation with average linkage and bootstrap support.

Limitations

  • The paper states that additional studies are required to better understand pathogenic mechanisms, especially early AD stages, and to uncover and validate resilience biomarkers.
  • Evident from the text: small group sizes (19 CP-AD, 12 P-AD, 31 N in Table 1), analysis restricted to hippocampal CA1 tissue microarray cores, and semiquantitative manual immunohistochemistry scoring.
  • Evident from the text: cross-sectional autopsy design cannot establish causality; the authors argue PMI effects are unlikely because groups did not differ significantly in PMI and intervals were under 24 hours.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0099897

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Expression levels of markers related to oxidative damage to DNA. Boxplots of 8-OHdG scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of H2AX scores attributed to nuclear (C) and cytoplasmic (D) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).
Figure 1 Expression levels of markers related to oxidative damage to DNA. Boxplots of 8-OHdG scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of H2AX scores attributed to nuclear (C) and cytoplasmic (D) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).CC BY · PubMed Central
Figure 2 Expression levels of markers related to DNA repair. Boxplots of p53 scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of BRCA1 scores attributed to nuclear (C) and cytoplasmic (D) staining. Boxplots of PTEN scores attributed to nuclear staining (E) and cytoplasmic (F) staining. Boxplots of phospho-AKT scores attributed to nuclear (G) and cytoplasmic (H) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).
Figure 2 Expression levels of markers related to DNA repair. Boxplots of p53 scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of BRCA1 scores attributed to nuclear (C) and cytoplasmic (D) staining. Boxplots of PTEN scores attributed to nuclear staining (E) and cytoplasmic (F) staining. Boxplots of phospho-AKT scores attributed to nuclear (G) and cytoplasmic (H) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).CC BY · PubMed Central
Figure 3 Expression levels of markers related to progression of cell cycle. Boxplots of Cdk4 scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of cyclin D scores attributed to nuclear (C) and cytoplasmic (D) staining. Boxplots of phospho-Rb scores attributed to nuclear (E) and cytoplasmic (F). Boxplots of E2F1 scores attributed to nuclear (G) and cytoplasmic (H) staining. Boxplots of Cdk1 scores attributed to nuclear (I) and cytoplasmic (J) staining. Boxplots of cyclin B scores attributed to nuclear (K) and cytoplasmic (L) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).
Figure 3 Expression levels of markers related to progression of cell cycle. Boxplots of Cdk4 scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of cyclin D scores attributed to nuclear (C) and cytoplasmic (D) staining. Boxplots of phospho-Rb scores attributed to nuclear (E) and cytoplasmic (F). Boxplots of E2F1 scores attributed to nuclear (G) and cytoplasmic (H) staining. Boxplots of Cdk1 scores attributed to nuclear (I) and cytoplasmic (J) staining. Boxplots of cyclin B scores attributed to nuclear (K) and cytoplasmic (L) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).CC BY · PubMed Central
Figure 4 Expression levels of markers related to cell-cycle inhibition. Boxplots of p27 scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of Cdk5 scores attributed to nuclear (C) and cytoplasmic (D) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).
Figure 4 Expression levels of markers related to cell-cycle inhibition. Boxplots of p27 scores attributed to nuclear (A) and cytoplasmic (B) staining. Boxplots of Cdk5 scores attributed to nuclear (C) and cytoplasmic (D) staining. CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).CC BY · PubMed Central
Figure 5 Staining patterns and expression levels of apoptosis marker. TUNEL staining of neurons is stronger in CP-AD (A) than in P-AD (B) or N (C). Boxplots of apoptosis scores (D). CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).
Figure 5 Staining patterns and expression levels of apoptosis marker. TUNEL staining of neurons is stronger in CP-AD (A) than in P-AD (B) or N (C). Boxplots of apoptosis scores (D). CP-AD, clinical-pathological Alzheimer’s disease (green boxes); P-AD, pathological Alzheimer’s disease (blue boxes); N, normal aging (red boxes).CC BY · PubMed Central
Figure 6 Hierarchical clustering analysis of CP-AD, P-AD and N samples. Hierarchical clustering was performed by using the expression values from the markers with differential expression between CP-AD and P-AD/N. Each row represents a single marker, and each column represents a sample. Red indicates high expression, and green indicates low expression. The cluster support was performed with the Bootstrap technique (black, 100% support; grey, 90–100%; blue, 80–90%; green, 70–80%; light yellow, 60–70%; dark yellow, 50–60%; magenta, 0–50%, red, 0%). CP-AD, clinical-pathological Alzheimer’s disease; P-AD, pathological Alzheimer’s disease; N, normal aging.
Figure 6 Hierarchical clustering analysis of CP-AD, P-AD and N samples. Hierarchical clustering was performed by using the expression values from the markers with differential expression between CP-AD and P-AD/N. Each row represents a single marker, and each column represents a sample. Red indicates high expression, and green indicates low expression. The cluster support was performed with the Bootstrap technique (black, 100% support; grey, 90–100%; blue, 80–90%; green, 70–80%; light yellow, 60–70%; dark yellow, 50–60%; magenta, 0–50%, red, 0%). CP-AD, clinical-pathological Alzheimer’s disease; P-AD, pathological Alzheimer’s disease; N, normal aging.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 0 Not valid · 34 Not checked · 56 Own results and interpretations

66 more claims · 1 with their cited sources checked

Create a free account to see all 98 claims and to verify the 49 references still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 13
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

1 retracted

Show all 117 references

Cited by

See all 100

Metadata

Authors
Silva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., de Bragança Pereira, C. A., Jacob-Filho, W., & Brentani, H.
Affiliations
  • Universidade de São Paulo (BR)
  • AC Camargo Hospital (BR)
Corresponding author
  • Silva, Aderbal R. T.
  • Grinberg, Lea T.
  • Rocha, Rafael M.
  • Carraro, Dirce M.
  • Brentani, Helena
Venue
PLoS ONE
Published
2014-06-17
Volume
9
Issue
6
Pages
e99897
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2129162505
Cited by
99
References
117
Citations by year
2026: 3 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 15 · 2019: 4 · 2018: 13 · 2017: 9 · 2016: 11 · 2015: 7 · 2014: 1
FWCI
6.22
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Fundação de Amparo à Pesquisa do Estado de São Paulo (11/01652-6, 2011/)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords
Alzheimer's disease, oxidative DNA damage, DNA repair, cell cycle regulation, neuronal cell death, postmitotic neurons, hippocampus, 8-hydroxy-2'-deoxyguanosine, H2AX, p53, BRCA1, PTEN, cyclins, cyclin-dependent kinases, p27, E2F1, normal aging
MeSH terms
Aged, 80 and over, Alzheimer Disease, Cell Cycle, DNA Damage, DNA Repair, Female, Hippocampus, Humans, Male, Neurons, Apoptosis, Oxidative Stress, Tissue Array Analysis, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0099897
The paper
Silva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., de Bragança Pereira, C. A., Jacob-Filho, W., & Brentani, H. (2014). Repair of Oxidative DNA Damage, Cell-Cycle Regulation and Neuronal Death May Influence the Clinical Manifestation of Alzheimer’s Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0099897

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.